WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company, announced the granting of non-qualified stock options to purchase 134,000 shares of its common stock to two new employees under its 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $0.65 per share, reflecting the closing price on August 1, 2025. Each option has a ten-year term, with 25% vesting on the first anniversary of employment commencement and the remaining 75% vesting in 36 equal monthly installments, contingent on continued service. These grants comply with Nasdaq Listing Rule 5635(c)(4).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.